Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Mirati Therapeutics Inc Market Cap
The Mirati Therapeutics Inc (MRTX) share price is expected to increase by 0.51% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered MRTX. Price targets range from $59.00 at the low end to $59.00 at the high end. The current analyst consensus for MRTX is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
Mirati Therapeutics Inc has a total of 1 Wall St Analyst ratings. There are 0 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a hold consensus rating, the expectation is that Mirati Therapeutics Inc will generate similar returns as the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| jay olson Oppenheimer | Buy | $62.0 | maintained | Oct 6, 2023 |
| gena wang Barclays | Buy | $71.0 | reiterated | Aug 9, 2023 |
| swapnil malekar Piper Sandler | Buy | $68.0 | rated | Apr 18, 2023 |
| umer raffat Evercore ISI | Buy | None | maintained | May 27, 2022 |
| gavin scott J.P. Morgan | Buy | $109.0 | maintained | May 5, 2022 |
| anupam rama J.P. Morgan | Buy | $199.0 | maintained | Nov 16, 2021 |
| edward white H.C. Wainwright | Buy | $247.0 | maintained | Sep 21, 2021 |
| bradley canino Stifel Nicolaus | Buy | $285.0 | initiatedcoverage | Apr 26, 2021 |
| salveen richter Goldman Sachs | Buy | $267.0 | maintained | Oct 26, 2020 |
| chris shibutani Goldman Sachs | Buy | None | maintained | Feb 25, 2020 |
| peter lawson Barclays | Buy | $120.0 | maintained | Jun 3, 2019 |
| leah r. cann Brookline Capital Markets | Buy | $65.0 | rated | Jan 15, 2019 |
| yatin suneja Guggenheim | Buy | $60.0 | reiterated | Aug 9, 2018 |
| shaunak deepak H.C. Wainwright | Buy | $10.0 | reiterated | Mar 10, 2017 |
| jonathan eckard Barclays | Buy | $27.0 | maintained | Jun 6, 2016 |
| heather behanna Wedbush | Buy | $27.0 | reiterated | Jun 6, 2016 |
| michael schmitz Ladenburg Thalmann & Co. | Buy | $50.0 | maintained | Sep 9, 2015 |
| roy buchanan JMP Securities | Buy | $50.0 | reiterated | Jun 1, 2015 |
| thomas wei Jefferies | Buy | $36.0 | initiatedcoverage | Dec 18, 2013 |
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
When did it IPO
0
Staff Count
587
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Charles M. Baum M.D., Ph.D.
Market Cap
$4.12B
In 2023, MRTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MRTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
AVT-USD
$46.44
ACAD-USD
$24.85
POWI-USD
$73.35
FOLD-USD
$13.56
$48.92
INSM-USD
$29.21
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
